Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $38,539 | $2,513,000 | $4,362,000 | $8,069,000 |
| Dep. & Amort. | $38,241 | $5,249,000 | $5,337,000 | $5,162,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$13,669 | -$1,647,000 | -$1,722,000 | -$18,395,000 |
| Other Non-Cash | -$7,679 | -$6,074,115 | $9,729,000 | $2,205,000 |
| Operating Cash Flow | $55,432 | $5,892,000 | $17,706,000 | -$2,959,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$60,637 | -$4,380,000 | -$6,827,000 | -$10,341,000 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$8,382 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | -$291 | $4,347,269 | -$587,000 | -$1,088,000 |
| Investing Cash Flow | -$69,310 | -$32,731 | -$7,414,000 | -$11,429,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$36,835 | $7,178,000 | -$3,108,000 | $7,279,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$602 | -$1,878,000 | -$61,000 | -$1,469,000 |
| Other Fin. Act. | $23,964 | -$5,256,610 | $9,154,000 | -$4,431,000 |
| Financing Cash Flow | -$13,473 | $43,390 | $5,985,000 | $1,379,000 |
| Forex Effect | -$4,852 | $12,751 | -$48,000 | $993,000 |
| Net Chg. in Cash | -$32,203 | $52,938,000 | -$29,231,000 | $29,231,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $367,337 | $0 | $29,231,000 | $0 |
| End Cash | $335,134 | $52,938,000 | $0 | $29,231,000 |
| Free Cash Flow | -$1,507 | $1,512,000 | $10,879,000 | -$13,300,000 |